MCID: PPL021
MIFTS: 49

Papilledema

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Papilledema

MalaCards integrated aliases for Papilledema:

Name: Papilledema 12 74 52 29 54 15 71
Edema of the Optic Disc 52
Choked Disk 52

Classifications:



External Ids:

Disease Ontology 12 DOID:146
ICD9CM 34 377.0
MeSH 43 D010211
NCIt 49 C3307
SNOMED-CT 67 423341008
ICD10 32 H47.1
UMLS 71 C0030353

Summaries for Papilledema

NIH Rare Diseases : 52 Papilledema is a condition in which increased pressure in or around the brain (intracranial pressure) causes swelling of the part of the optic nerve inside the eye (optic disc ). Symptoms of increased intracranial pressure include headache or nausea and vomiting. Vision problems are not common initially, but may include short flickers of gray vision, blurred or double vision, and decreased field of vision or ability to see colors. Both eyes are usually affected. Papilledema by definition is caused by increased cranial pressure. Diagnosis includes a thorough eye exam by an ophthalmologist . Brain imaging studies (for example CT scan or MRI ) are used to find the cause of the increased intracranial pressure. Treatment depends on the cause of the increased pressure but may include medications, surgery and/or weight management.

MalaCards based summary : Papilledema, also known as edema of the optic disc, is related to intracranial hypertension and hydrocephalus, and has symptoms including edema An important gene associated with Papilledema is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Response to elevated platelet cytosolic Ca2+. The drugs Doxycycline and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Papilledema or papilloedema is optic disc swelling that is caused by increased intracranial pressure due... more...

Related Diseases for Papilledema

Diseases related to Papilledema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 765)
# Related Disease Score Top Affiliating Genes
1 intracranial hypertension 32.4 SERPINC1 SERPINA3 F3 F2 APOH
2 hydrocephalus 31.6 VEGFA TP53 SYP SERPINA3 ARSB ACE
3 optic papillitis 31.5 NLRP3 CRP CD40LG CD4 ACE
4 thrombophilia due to thrombin defect 30.7 SERPINC1 F3 F2 APOH
5 abducens nerve disease 30.5 SERPINC1 F2 CRP
6 meningitis 30.5 VEGFA NLRP3 CRP CD40LG
7 sagittal sinus thrombosis 30.4 SERPINC1 F3 F2
8 intracranial hypertension, idiopathic 30.4 PCLO OGG1 F3 F2
9 lateral sinus thrombosis 30.3 SERPINC1 F3 F2
10 vasculitis 30.2 SERPINA3 CRP CD40LG APOH
11 hypertensive retinopathy 30.2 VEGFA CRP ACE
12 thrombosis 30.1 SERPINC1 SERPINA3 F3 F2 CD40LG APOH
13 cerebral sinovenous thrombosis 30.1 F3 F2 APOH
14 apnea, obstructive sleep 30.1 VEGFA CRP ACE
15 osteosclerotic myeloma 30.1 VEGFA MYOM2 CD40LG
16 migraine with or without aura 1 30.0 F2 CRP CD40LG APOH ACE
17 polyneuropathy 30.0 VEGFA CRP CD40LG ACE
18 meningioma, familial 30.0 VEGFA TP53 SYP SERPINA3
19 plasma cell neoplasm 29.9 TP53 SERPINA3 MYOM2 CD40LG
20 homocysteinemia 29.9 SERPINC1 F2 CRP APOH
21 neurofibroma 29.9 VEGFA TP53 SYP
22 cinca syndrome 29.9 NLRP3 IL1RN IL1R1
23 nonarteritic anterior ischemic optic neuropathy 29.8 VEGFA SERPINC1 F2 CRP APOH ACE
24 hypertensive encephalopathy 29.8 VEGFA F2 ACE
25 brucellosis 29.8 IL1RN CRP CD40LG
26 multiple cranial nerve palsy 29.7 CRP ACE
27 mantle cell lymphoma 29.7 VEGFA TP53 STAT3 CD40LG
28 thrombocytosis 29.7 SERPINC1 F3 F2 CRP
29 syphilitic meningitis 29.6 CD40LG CD4
30 retinal vascular occlusion 29.6 VEGFA SERPINC1 F2 CRP APOH
31 acquired immunodeficiency syndrome 29.5 TP53 CRP CD40LG CD4
32 hemangioma 29.5 VEGFA TP53 SYP F3 F2
33 retinal vascular disease 29.5 VEGFA CRP ACE
34 central retinal vein occlusion 29.5 VEGFA SERPINC1 F3 F2 APOH
35 carotid artery disease 29.5 F3 CRP ACE
36 asymptomatic neurosyphilis 29.4 CD40LG CD4
37 thrombophlebitis 29.4 SERPINC1 F3 F2 CRP CD40LG APOH
38 hemorrhagic disease 29.4 SERPINC1 F3 F2 CRP CD40LG
39 neuroretinitis 29.4 CRP CD40LG CD4 ACE
40 neurosarcoidosis 29.4 CRP CD4 ACE
41 aseptic meningitis 29.3 NLRP3 IL1RN IL1R1 CRP CD40LG
42 epidemic typhus 29.3 CRP CD40LG CD4
43 optic nerve disease 29.2 VEGFA SERPINA3 CRP CD40LG CD4 ACE
44 pleural empyema 29.2 F2 CRP CD40LG CD4
45 crohn's disease 29.2 STAT3 NLRP3 CRP CD4
46 chorioretinitis 29.2 VEGFA CD40LG CD4 ACE
47 antiphospholipid syndrome 29.2 SERPINC1 F3 F2 CRP CD40LG APOH
48 lymphatic system disease 29.1 TP53 SERPINA3 CD40LG CD4
49 meningoencephalitis 29.1 SERPINA3 CRP CD40LG CD4
50 cerebrovascular disease 29.0 SERPINA3 F2 CRP CD40LG APOH ACE

Graphical network of the top 20 diseases related to Papilledema:



Diseases related to Papilledema

Symptoms & Phenotypes for Papilledema

UMLS symptoms related to Papilledema:


edema

GenomeRNAi Phenotypes related to Papilledema according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.75 ARSB
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.75 ARSB
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.75 ARSB F2 PCLO STAT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.75 IL1R1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.75 ARSB F2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.75 F2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.75 F2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-15 9.75 PCLO
9 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.75 PCLO
10 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.75 PCLO
11 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.75 STAT3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.75 IL1R1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.75 STAT3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-27 9.75 ARSB
15 Increased shRNA abundance (Z-score > 2) GR00366-A-40 9.75 PCLO
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.75 ARSB F2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.75 F2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.75 STAT3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.75 F2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.75 IL1R1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-90 9.75 PCLO
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.75 IL1R1

MGI Mouse Phenotypes related to Papilledema:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 ACE APOH ARSB CD4 CD40LG CRP
2 hematopoietic system MP:0005397 10.34 ACE ARSB CD4 CD40LG F2 F3
3 behavior/neurological MP:0005386 10.31 ACE ARSB F2 F3 IL1R1 OGG1
4 cardiovascular system MP:0005385 10.3 ACE ARSB CD40LG CRP F2 F3
5 immune system MP:0005387 10.3 ACE CD4 CD40LG CRP F2 F3
6 cellular MP:0005384 10.29 ARSB CD4 CD40LG F2 F3 IL1R1
7 mortality/aging MP:0010768 10.24 ACE APOH CD4 CD40LG F2 F3
8 integument MP:0010771 10.17 CD4 CD40LG F2 F3 IL1R1 IL1RN
9 nervous system MP:0003631 10.1 ARSB CD4 CD40LG F2 F3 IL1R1
10 liver/biliary system MP:0005370 10.01 ACE IL1R1 NLRP3 OGG1 SERPINC1 STAT3
11 normal MP:0002873 9.9 CD4 F2 F3 IL1R1 NLRP3 OGG1
12 neoplasm MP:0002006 9.87 ACE F3 IL1R1 OGG1 STAT3 TP53
13 renal/urinary system MP:0005367 9.61 ACE ARSB CD40LG IL1R1 NLRP3 SERPINC1
14 reproductive system MP:0005389 9.32 ACE ARSB CD40LG F2 IL1RN NLRP3

Drugs & Therapeutics for Papilledema

Drugs for Papilledema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
2
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
3
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
4
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
5 Pharmaceutical Solutions Phase 4
6 Mitogens Phase 4
7 Endothelial Growth Factors Phase 4
8
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
10
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
11
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
12
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
13
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
14
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
15
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
16
Acetazolamide Approved, Vet_approved Phase 3 59-66-5 1986
17 Analgesics, Non-Narcotic Phase 2, Phase 3
18 Analgesics Phase 2, Phase 3
19 Anti-Inflammatory Agents Phase 2, Phase 3
20 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
21 Gastrointestinal Agents Phase 2, Phase 3
22 Antineoplastic Agents, Hormonal Phase 2, Phase 3
23
protease inhibitors Phase 2, Phase 3
24 Hormones Phase 2, Phase 3
25 Antiemetics Phase 2, Phase 3
26 Hormone Antagonists Phase 2, Phase 3
27 HIV Protease Inhibitors Phase 2, Phase 3
28 glucocorticoids Phase 2, Phase 3
29 BB 1101 Phase 2, Phase 3
30 Respiratory System Agents Phase 2, Phase 3
31 Antitussive Agents Phase 2, Phase 3
32 Narcotics Phase 2, Phase 3
33 Fibrinolytic Agents Phase 2, Phase 3
34 Platelet Aggregation Inhibitors Phase 2, Phase 3
35 Antipyretics Phase 2, Phase 3
36 Cyclooxygenase Inhibitors Phase 2, Phase 3
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
38 Analgesics, Opioid Phase 2, Phase 3
39 Antihypertensive Agents Phase 3
40 Endothelin Receptor Antagonists Phase 3
41 diuretics Phase 3
42 Anticonvulsants Phase 3
43 Carbonic Anhydrase Inhibitors Phase 3
44
Ranibizumab Approved Phase 2 347396-82-1 459903
45
Bevacizumab Approved, Investigational Phase 2 216974-75-3
46 Angiogenesis Inhibitors Phase 2
47 Antirheumatic Agents Phase 1, Phase 2
48 Interleukin 1 Receptor Antagonist Protein Phase 1, Phase 2
49
Nepafenac Approved, Investigational 78281-72-8 151075
50
Bromfenac Approved 91714-94-2 60726

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment Unknown status NCT02149615 Phase 4
2 Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
3 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
4 Ozurdex in Treatment of Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
5 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
6 Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy Recruiting NCT02377271 Phase 3 bosentan;placebo
7 The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure Active, not recruiting NCT04431882 Phase 2, Phase 3
8 Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss Terminated NCT03501966 Phase 3 Acetazolamide
9 Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study. Completed NCT02017444 Phase 2 AZD4017
10 Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe Active, not recruiting NCT03071055 Phase 2 Ranibizumab Injection [Lucentis]
11 A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease Terminated NCT00069329 Phase 1, Phase 2 anakinra
12 Evaluation of the Feasibility, Safety and Efficacy of Venous Stenting for Internal Jugular Vein Stenosis Unknown status NCT03373292 Phase 1
13 Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Unknown status NCT03273179
14 Ocular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination Unknown status NCT02992262
15 OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension Unknown status NCT02665858
16 Non-invasive Absolute Intracranial Pressure (ICP) Measurement in Patients With Open-angle Glaucoma and Papilledema Unknown status NCT02410148
17 Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension Unknown status NCT02394067
18 Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy Unknown status NCT03490318
19 Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension Unknown status NCT02143258
20 Retinal Nerve Fibre Layer in Uveitic Secondary Glaucoma Completed NCT01170481
21 Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine? Completed NCT00873613
22 LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes Completed NCT01318941 Ranibizumab
23 Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery Completed NCT01847638 Prolensa (bromfenac 0.07%);Ilevro (nepafenac 0.3%)
24 D-dimer and the Use of Anticoagulation in IIH Completed NCT03963336 Early Phase 1 LMWH;acetazolamide
25 The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis Completed NCT00924859
26 Non-Invasive Measurement of Absolute Intracranial Pressure in Patients With Mass Effective Brain Tumors Completed NCT03641443
27 MRI for Non-invasive Evaluation of Brain Stress Completed NCT01898650
28 Hyperphenylalaninemia in Cerebral Malaria Completed NCT00338520
29 The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study Completed NCT00071903
30 Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure Recruiting NCT03286426
31 Measurement of Optic Nerve Sheath Diameter in Children Without the Increased Intracranial Pressure Recruiting NCT03178760
32 Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension Recruiting NCT04032379
33 Assessment of Raised Intracranial Pressure in Patients With Idiopathic Intracranial Hypertension by Optic Nerve Sheath Diameter and Transcranial Doppler Measurements Recruiting NCT04314128
34 Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases Active, not recruiting NCT03753893
35 Evaluating Raised Intracranial Pressure Using MR Elastography Active, not recruiting NCT03096743
36 Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives Active, not recruiting NCT01861080
37 Validation of a Non-Invasive Intracranial Pressure (ICP) Device by Comparison With Implanted Intracranial Pressure Monitoring Instrumentation or Lumbar Puncture Active, not recruiting NCT03865576
38 Biomarker for Hypophosphatasia Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL Active, not recruiting NCT02603042
39 A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema Available NCT01487044 Macugen (Pegaptanib Sodium)
40 A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis Not yet recruiting NCT04187469 Moxifloxacin, Isoniazid, Rifampicin;Rifampicin,Isoniazid,Pyrazinamide,Ethambutol
41 Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP) Not yet recruiting NCT02513914
42 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834
43 Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure Withdrawn NCT02558309

Search NIH Clinical Center for Papilledema

Genetic Tests for Papilledema

Genetic tests related to Papilledema:

# Genetic test Affiliating Genes
1 Papilledema 29

Anatomical Context for Papilledema

MalaCards organs/tissues related to Papilledema:

40
Brain, Eye, Spinal Cord, Pineal, Retina, Endothelial, Kidney

Publications for Papilledema

Articles related to Papilledema:

(show top 50) (show all 2848)
# Title Authors PMID Year
1
A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. 54 61
7536209 1995
2
Review of non-invasive intracranial pressure measurement techniques for ophthalmology applications. 61
31704702 2020
3
Deep Learning and Transfer Learning for Optic Disc Laterality Detection: Implications for Machine Learning in Neuro-Ophthalmology. 61
31453913 2020
4
Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use. 61
32469180 2020
5
Update in Pediatric Pseudotumor Cerebri Syndrome. 61
32422670 2020
6
Etiology of Papilledema in Patients in the Eye Clinic Setting. 61
32484553 2020
7
Quantitative topographic curvature maps of the posterior eye utilizing optical coherence tomography. 61
32568982 2020
8
Bilateral Squamosal Suture Craniosynostosis Presenting with Abducens Nerve Palsy and Severe Papilledema. 61
32217173 2020
9
[Differential diagnosis of papilledema and macular exudation-the exophytically growing juxtapapillary retinal capillary hemangioma]. 61
32577810 2020
10
A Case of HaNDL Presenting With Papilledema. 61
32167161 2020
11
Asymptomatic Papilledema in a 64-Year-Old Man. 61
32525514 2020
12
Idiopathic Intracranial Hypertension: Contemporary Management and Endovascular Techniques. 61
32419730 2020
13
Transient vision loss after optic nerve sheath fenestration. 61
31537140 2020
14
A rare case of schwannoma arising from dura mater of the petrosal surface in the posterior cranial fossa. 61
32569764 2020
15
Reductions in bilateral transverse sinus pressure gradients with unilateral transverse venous sinus stenting for idiopathic intracranial hypertension. 61
32482835 2020
16
Spontaneous Skull Base Cerebrospinal Fluid Leaks and Their Relationship to Idiopathic Intracranial Hypertension. 61
32551921 2020
17
Central Venous Obstruction-Induced Intracranial Hypertension in Hemodialysis Patients: An Underrecognized Cause of Elevated Intracranial Pressure. 61
32392024 2020
18
Ocular manifestations in rheumatoid arthritis, connective tissue disease and vasculitis: a systematic review and meta-analysis. 61
32358156 2020
19
Optic nerve sheath diameter ultrasonography for elevated intracranial pressure detection. 61
32383326 2020
20
The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). 61
32285309 2020
21
Clival Chordoma in an Adolescent: A Perspective from Primary Care. 61
32438537 2020
22
The prevalence of papilledema in patients with migraine: a crucial cooccurrence of migraine and idiopathic intracranial hypertension. 61
32458251 2020
23
Imaging Methods for Differentiating Pediatric Papilledema from Pseudopapilledema: A Report by the American Academy of Ophthalmology. 61
32386809 2020
24
Optic disc drusen: a systematic review : Up-to-date and future perspective. 61
32383130 2020
25
Unusual presentation of idiopathic intracranial hypertension. 61
32475825 2020
26
Reliability of optic disc edema area in estimating the severity of papilledema in patients with POEMS syndrome. 61
32429967 2020
27
Long-term Kinetic Papilledema Improvement After Venous Sinus Stenting in Idiopathic Intracranial Hypertension. 61
32399641 2020
28
Papilledema in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Pediatric Case and Review of the Literature. 61
32468920 2020
29
Long-term outcome of large sylvian arachnoid cysts: the role of surgery has been exaggerated. 61
32413863 2020
30
Derivation of a bedside score (MASH-P) to predict 6-month mortality in tuberculous meningitis. 61
32408191 2020
31
Not Just Another Headache: Cerebral Venous Sinus Thrombosis in a Patient With Isolated Antithrombin III Deficiency. 61
32494550 2020
32
Presentation and Progression of Papilledema in Cerebral Venous Sinus Thrombosis. 61
31926886 2020
33
Intracranial Hypertension Following Gunshot Wound to the Torcula: Case Report and Literature Review. 61
32006734 2020
34
Effect of Shunting on Visual Outcomes and Headache in Patients with Idiopathic Intracranial Hypertension. 61
32474095 2020
35
Automatic detection of rare pathologies in fundus photographs using few-shot learning. 61
32028213 2020
36
Neuro-Ophthalmic Manifestations of Intracranial Malignancies. 61
32282510 2020
37
Visual failure and sinus thrombosis following depressed skull fracture: management with single session lumboperitoneal shunt and sinus decompression -case report. 61
29363350 2020
38
Artificial Intelligence to Detect Papilledema from Ocular Fundus Photographs. 61
32286748 2020
39
Data on fundus images for vessels segmentation, detection of hypertensive retinopathy, diabetic retinopathy and papilledema. 61
32154339 2020
40
Outcome of idiopathic intracranial hypertension after laparoscopic sleeve gastrectomy. 61
32409117 2020
41
AI for the Eye - Automated Assistance for Clinicians Screening for Papilledema. 61
32286747 2020
42
Idiopathic Intracranial Hypertension Without Papilledema With Improvement in Visual Field Defect Following Optic Nerve Sheath Fenestration: Comment. 61
32358434 2020
43
Idiopathic Intracranial Hypertension Without Papilledema With Improvement in Visual Field Defect Following Optic Nerve Sheath Fenestration: Response. 61
32358437 2020
44
Posterior Globe Flattening without Papilledema in Idiopathic Intracranial Hypertension. 61
32395152 2020
45
[Eye changes in space : New insights into clinical aspects, pathogenesis and prevention]. 61
32347333 2020
46
Atypical presentation of spinal intramedullary astrocytoma in a patient presenting with isolated signs of intracranial hypertension. 61
32273494 2020
47
Cerebral Venous Sinus Thrombosis in Adults with Prothrombotic Conditions: A Systematic Review and a Case from Our Institution. 61
32411555 2020
48
A systematic review of surgical treatments of idiopathic intracranial hypertension (IIH). 61
32335853 2020
49
Coexistence of papilledema and pseudopapilledema after remission of idiopathic intracranial hypertension by bariatric surgery. 61
32159598 2020
50
Anterior ischemic optic neuropathy in a patient with papilledema from idiopathic intracranial hypertension. 61
31956730 2020

Variations for Papilledema

Expression for Papilledema

Search GEO for disease gene expression data for Papilledema.

Pathways for Papilledema

Pathways related to Papilledema according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 VEGFA TP53 STAT3 IL1RN IL1R1 CD40LG
2
Show member pathways
13.03 VEGFA TP53 SERPINC1 SERPINA3 F3 F2
3
Show member pathways
12.25 TP53 STAT3 IL1R1 CD40LG CD4
4
Show member pathways
12.07 TP53 SERPINA3 F2 CRP
5 11.25 VEGFA TP53 STAT3
6 11.19 STAT3 IL1RN IL1R1
7
Show member pathways
10.81 VEGFA STAT3 CRP
8 10.53 NLRP3 IL1R1 F2
9 10.08 VEGFA STAT3 SERPINA3

GO Terms for Papilledema

Cellular components related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 VEGFA SERPINC1 SERPINA3 IL1RN F3 F2
2 external side of plasma membrane GO:0009897 9.72 IL1R1 F2 CD40LG CD4 ACE
3 collagen-containing extracellular matrix GO:0062023 9.65 SERPINC1 SERPINA3 F3 F2 APOH
4 cell surface GO:0009986 9.5 VEGFA IL1R1 F3 CD40LG CD4 ARSB
5 extracellular region GO:0005576 9.44 VEGFA SERPINC1 SERPINA3 NLRP3 IL1RN IL1R1

Biological processes related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 VEGFA TP53 STAT3 F3 CRP
2 hemostasis GO:0007599 9.58 SERPINC1 F3 F2
3 inflammatory response GO:0006954 9.5 STAT3 SERPINA3 NLRP3 IL1RN IL1R1 CRP
4 acute-phase response GO:0006953 9.46 STAT3 SERPINA3 F2 CRP
5 negative regulation of fibrinolysis GO:0051918 9.43 F2 APOH
6 regulation of blood coagulation GO:0030193 9.43 SERPINC1 F2 APOH
7 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.37 VEGFA TP53
8 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.32 VEGFA ACE
9 cytokine-mediated signaling pathway GO:0019221 9.17 VEGFA TP53 STAT3 IL1RN IL1R1 F3

Molecular functions related to Papilledema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.46 VEGFA SERPINC1 F2 APOH
2 identical protein binding GO:0042802 9.28 VEGFA TP53 SYP STAT3 SERPINC1 NLRP3
3 protease binding GO:0002020 9.26 TP53 SERPINC1 IL1R1 F3

Sources for Papilledema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....